表紙
市場調查報告書

膽囊癌治療藥的全球市場:2019年∼2023年

Gallbladder Cancer Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 906356
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
Back to Top
膽囊癌治療藥的全球市場:2019年∼2023年 Gallbladder Cancer Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
出版日期: 2019年08月09日內容資訊: 英文 133 Pages
簡介

全球膽囊癌治療藥市場上,開發中國家的膽囊癌的發生率高,膽囊癌的危險因素增加,治療方法的化療使用等成為成長促進因素,在預測期間內預計將以約5%的年複合成長率擴大。但,化療伴隨的副作用,膽囊癌的診斷抗原的缺乏,已開發國家的疾病發生率低等的不穩定要素,可能妨礙在預測期間內全球膽囊癌治療藥產業的成長。

本報告提供全球膽囊癌治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 開發平台分析

第7章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2018年∼2023年)
  • 聯合治療
  • 單劑療法
  • 市場機會:各類型

第8章 客戶形勢

第9章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

  • 強力的開發平台
  • 標靶治療的出現
  • 策略性聯盟

第13章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi

第15章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第16章 關於TECHNAVIO

目錄
Product Code: IRTNTR31864

About this market

Technavio's gallbladder cancer therapeutics market considers sales from both combination therapy and monotherapy. Our analysis also considers the sales of gallbladder cancer therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high therapeutic efficacy of these drugs will play a significant role in the combination therapy segment to maintain its market position. Also, our global gallbladder cancer therapeutics market report looks at factors such as strong incidence of gallbladder cancer in developing countries, rising risk factors for gall bladder cancer, and use of chemotherapy as a therapeutic approach. However, uncertainties in the side effect associated with chemotherapy, lack of diagnostic antigens for gallbladder cancer, and low incidence rate of disease in developed countries may hamper the growth of the global gallbladder cancer therapeutics industry over the forecast period.

Overview

Rising risk factors for gallbladder cancer

Rise in the occurrence of cholelithiasis, chronic inflammation, and gall bladder polyps will increase the risk of developing gall bladder cancer, inducing the demand gallbladder cancer therapeutics. The rising availability of financial assistance programs is further helping patients in availing these high-cost treatments. This will lead to the expansion of the global gallbladder cancer therapeutics market at a CAGR of almost 5% during the forecast period.

The advent of targeted therapy

The global gallbladder cancer therapeutics market is witnessing the advent of immunotherapy as a potential therapeutic for the treatment of biliary tract cancer, including gallbladder cancer. The ongoing research in this is expected to facilitate the approval process of this drug. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global gallbladder cancer therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global gallbladder cancer therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gallbladder cancer therapeutics manufacturers, that include Bristol-Myers Squibb Co., Eli Lilly, and Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi.

Also, the gallbladder cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Strong pipeline
  • Advent of targeted therapy
  • Strategic alliances

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Some late-stage molecules for biliary tract cancer and global gallbladder cancer
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by type
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Incidence rate of gallbladder cancer in various developing countries - 2015
  • Exhibit 44: Frequency of side effects associated with chemotherapy
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 52: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 53: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 54: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 55: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 56: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 57: Eli Lilly and Co. - Vendor overview
  • Exhibit 58: Eli Lilly and Co. - Business segments
  • Exhibit 59: Eli Lilly and Co. - Organizational developments
  • Exhibit 60: Eli Lilly and Co. - Geographic focus
  • Exhibit 61: Eli Lilly and Co. - Segment focus
  • Exhibit 62: Eli Lilly and Co. - Key offerings
  • Exhibit 63: Eli Lilly and Co. - Key customers
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 71: Pfizer Inc. - Vendor overview
  • Exhibit 72: Pfizer Inc. - Business segments
  • Exhibit 73: Pfizer Inc. - Organizational developments
  • Exhibit 74: Pfizer Inc. - Geographic focus
  • Exhibit 75: Pfizer Inc. - Segment focus
  • Exhibit 76: Pfizer Inc. - Key offerings
  • Exhibit 77: Pfizer Inc. - Key customers
  • Exhibit 78: Sanofi - Vendor overview
  • Exhibit 79: Sanofi - Business segments
  • Exhibit 80: Sanofi - Organizational developments
  • Exhibit 81: Sanofi - Geographic focus
  • Exhibit 82: Sanofi - Segment focus
  • Exhibit 83: Sanofi - Key offerings
  • Exhibit 84: Sanofi - Key customers
  • Exhibit 85: Validation techniques employed for market sizing
  • Exhibit 86: Definition of market positioning of vendors
Back to Top